Last reviewed · How we verify
Cu-64 SARTATE and Cu-67 SARTATE — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Cu-64 SARTATE and Cu-67 SARTATE (Cu-64 SARTATE and Cu-67 SARTATE) — Clarity Pharmaceuticals Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cu-64 SARTATE and Cu-67 SARTATE TARGET | Cu-64 SARTATE and Cu-67 SARTATE | Clarity Pharmaceuticals Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cu-64 SARTATE and Cu-67 SARTATE CI watch — RSS
- Cu-64 SARTATE and Cu-67 SARTATE CI watch — Atom
- Cu-64 SARTATE and Cu-67 SARTATE CI watch — JSON
- Cu-64 SARTATE and Cu-67 SARTATE alone — RSS
Cite this brief
Drug Landscape (2026). Cu-64 SARTATE and Cu-67 SARTATE — Competitive Intelligence Brief. https://druglandscape.com/ci/cu-64-sartate-and-cu-67-sartate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab